Short Communication

Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news?

R Handgretinger*,1, W Leung1, K Ihm2, P Lang3, T Klingebiel3 and D Niethammer2

1Division of Stem Cell Transplantation, St Jude Children’s Research Hospital, Mail stop 321, 332 N. Lauderdale St., Memphis, TN 38105, USA; 2Children’s University Hospital, Tuebingen, Hoppe-Seyler-Strasse 1, 72076 Tuebingen, Germany; 3Children’s University Hospital, Frankfurt, Theodor Stern Kai 7, 60580 Frankfurt, Germany

We analysed the effect of graft-contaminating tumour cells on the long-term survival of 24 patients with high-risk neuroblastoma and found that patients whose grafts contained detectable neuroblastoma cells had a significantly higher probability of survival than did patients with no detectable tumour cells. Estimated contamination of the graft by more than 2000 tumour cells was associated with a significantly higher probability of survival than contamination with fewer tumour cells. We hypothesise that the presence of a critical number of graft-contaminating neuroblastoma cells can elicit a protective antitumour immune response after autologous transplantation.

British Journal of Cancer (2003) 88, 1874–1877. doi:10.1038/sj.bjc.6601014 www.bjcancer.com
© 2003 Cancer Research UK

Keywords: neuroblastoma; high-dose chemotherapy; CD34 selection; lymphodepletion; T-cell homeostatic proliferation

Induction of a tumour-specific immune response is a major goal in the treatment of patients with solid tumours (Rosenberg, 2001), and promising clinical results have been obtained in the case of some malignancies (Jager et al, 2002). Most vaccination strategies have been clinically evaluated under conditions of steady-state haematopoiesis, but not during lymphoid reconstitution. However, the growth inhibition of sarcoma cells in mice during lymphopenia induced by sublethal total body irradiation is known for a long time (Hellstrom et al, 1978). Recently, a specific and long-lasting antitumour immune response was shown to be induced in RAG1 knockout mice by vaccination during early lymphoid reconstitution (Hu et al, 2002). In another study, greater activity against tumours was observed when mice were vaccinated immediately after myeloid ablative therapy and autologous bone marrow rescue (Borrello et al, 2000); similar approaches have been discussed for humans (Kwak, 1998).

A clinical scenario that most closely mimics those described in mice is autologous transplantation with a tumour-contaminated stem cell graft during chemotherapy-induced neutropenia and lymphopenia. Such a scenario is often encountered in children with high-risk neuroblastoma, up to 82% of whom have tumour contamination of their peripheral stem cell grafts (Lode et al, 1997; Leung et al, 1998; Burchill et al, 2001).

The observations described above suggested to us that the reinfusion of graft-contaminating tumour cells during chemotherapy-induced lymphopenia, and the subsequent reconstitution of lymphopoiesis, might exert a protective effect against relapse. We therefore retrospectively analysed the long-term survival and clinical course of 24 children with high-risk neuroblastoma who underwent autologous transplantation with stem cells purged by positive selection of CD34+ cells.

PATIENTS AND METHODS

Stem cell mobilisation and myeloablative therapy

A total of 24 consecutively treated children with high-risk neuroblastoma (23 with stage 4 disease and one with stage 3 disease with N-myc amplification) were included into the retrospective analysis. In all patients, peripheral blood stem cells (PBSC) were mobilised and collected as described (Klingebiel et al, 1998). Myeloablative therapy consisted of melphalan, etoposide, and carboplatin; some patients also had high-dose mIBG therapy, given as described (Klingebiel et al, 1998). Of the 24 patients, 21 received post-transplant immunotherapy with an antibody (ch14.18) to the tumour-associated disialoganglioside GD2 (Handgretinger et al, 2002). All transplants were given between January 1996 and February 1998. Median follow-up was 5 years.

Stem cell purging and detection of residual neuroblastoma cells

The PBSCs of all patients were purged by positive selection of CD34+ stem cells by high-gradient magnetic-activated cell sorting (Handgretinger et al, 1998). The median purity of the CD34+ stem cells after positive selection was 97.6%. All CD34+ stem cell grafts were examined for the presence of contaminating neuroblastoma cells by immunofluorescence with the chimeric anti-GD2 antibody delta ch14.18 (Handgretinger et al, 2002). This technique
can detect contamination as low as one neuroblastoma cell in $10^5$ normal cells.

Statistical analysis

Distribution of the probability of relapse-free survival was estimated by the method of Kaplan and Meier (1958). Differences in the estimated probability of survival were tested by using log-rank statistics. The number of tumour cells in the grafts of patients who did and did not experience relapse was compared by using the Wilcoxon rank-sum test. All tests were two-sided.

RESULTS

The median number of transplanted purified CD34$^+$ stem cells was $5.1 \times 10^6$ kg$^{-1}$ body weight (range 0.9 - 39.8 $\times 10^6$ kg$^{-1}$) and the median to reach $0.5 \times 10^9$ neutrophiles after myeloablative therapy was 12 days (range 8-24 days). Lymphoid reconstitution was analysed in eight patients and the median to reach $>0.2 \times 10^9$ and $>1 \times 10^9$ CD$^+$ T lymphocytes was 21 days and 6 months, respectively. Before purging, 17 of 22 grafts tested contained various numbers of tumour cells ($0.82 \times 10^9 - 5.2 \times 10^9$ tumour cells per graft). Tumour contamination was evaluated in all 24 grafts after purging. Four of the 24 grafts contained measurable neuroblastoma cells (a total of 2300 – 74 000 neuroblastoma cells per graft) and all four patients are long-term survivors after autografting. In contrast, the probability of 5-year survival among the other 20 patients was $5.1 \times 10^9$ per 10$^5$ transplanted mononuclear cells) the possible absolute number of tumour cells in the 20 grafts that had no measurable neuroblastoma cells (a total of 2300 – 74 000 neuroblastoma cells per graft) and all four patients are long-term survivors after autografting. In contrast, the probability of 5-year survival among the other 20 patients was $33 \pm 11\%$ ($P = 0.04$, log-rank test) (Figure 1). All deaths in this patient group were caused by relapse. These data suggest that graft-contaminating tumour cells induced a protective effect.

In order to estimate whether there would be a threshold number of protective graft-contaminating tumour cells, we calculated on the basis of the lower detection limit of our assay (one tumour cell per 10$^5$ transplanted mononuclear cells) the possible absolute number of neuroblastoma cells in the 20 grafts that had no measurable tumour cells. We assumed maximal contamination based on our observation of tumour-cell contamination in 17 of the 22 evaluable unpurged grafts and the fact that more sensitive methods of tumour detection, such as polymerase chain reaction, revealed a survival discriminant value of approximately 2000 tumour cells (Figure 2A). As shown in Figure 2B, the probability of 5-year survival was 88 ± 12% for patients estimated to be infused with more than 2000 tumour cells ($n = 8$) but only 19 ± 10% for those estimated to be infused with fewer than 2000 tumour cells ($n = 16$) ($P = 0.006$, log-rank rest). The number of transplanted CD34$^+$ stem cells or the remission status at the time of autologous transplantation had no influence on the outcome (data not shown).

DISCUSSION

Our observations suggest that high-dose chemotherapy followed by a neuroblastoma-contaminated autograft induces an antineuroblastoma effect. The post-transplant lymphopenia induced by myeloablative chemotherapy and the subsequent homeostasis-driven proliferation of T cells may favour the induction of a tumour-specific immune response, as recently observed in mice (Dummer et al, 2002) and as discussed by Maine and Mule (2002). In addition, mice vaccinated with modified autologous tumour cells after transplantation had a higher probability of disease-free
survival than did mice that were vaccinated in the absence of transplantation (Borrello et al, 2000). Moreover, tumour lysate-pulsed dendritic cells were able to elicit an effective antitumour immune response during early lymphoid recovery in a murine weakly immunogenic tumour model (Asavaroengchai et al, 2002). Altogether these findings suggest that exposure to tumour vaccines might be effective in inducing antitumour immunity during the post-transplant period of immune recovery. More recently, a high response rate has been reported in patients with metastatic melanoma after a nonmyeloablative lymphodepletion followed by adoptive transfer of autologous highly selected tumour-reactive T cells directed against overexpressed self-derived differentiation antigens (Dudley et al, 2002). The lymphodepletion in this setting may have led to disruption of homeostatic T-cell regulation or to abrogation of tolerogenic mechanisms. The reconstitution of CD3+ T lymphocytes occurred mainly during the first 6 months after autografting and is similar to published data on immune reconstitution after transplantation of highly purified autologous CD34+ stem cells (Heitger et al, 1999).

The use of purified CD34+ stem cells may offer an opportunity to reshape the repertoire of the reconstituting ‘naïve’ T lymphocytes to include tumour-associated self-antigens, thus overcoming any tumour-induced suppression of antitumour immunity (Sondak et al, 1991).

What could render autologous tumour cells immunogenic in the post-transplant period? Tumour-associated antigens (TAA), which are mostly tissue-specific or differentiation antigens encoded by normal genes (Boon and Old, 1997), are targets for a potential immune response (Nanda and Sercarz, 1995; Pardoll, 1999). TAA, including NY-ESO-1, MAGE-1, and MAGE-3, have been described in neuroblastoma (Soling et al, 1999). In addition, it is conceivable that the graft-contaminating neuroblastoma cells are altered through the freezing and thawing process of the graft, which might render them immunogenic after infusion into the patient. It has been shown that cell freezing can induce stress proteins such as heat-shock proteins (Liu et al, 2000) and that heat-shock proteins can be bound and processed by dendritic cells (Schild and Ramnensee, 2000). It has also been demonstrated that stressed apoptotic tumour cells can stimulate dendritic cells and induce specific cytotoxic T cells (Feng et al, 2002). The post-transplant treatment with the chimeric antibody ch14.18 may also have contributed, since antibody-induced apoptosis of neuroblastoma cells can also promote phagocytosis by dendritic cells and crosspriming of T cells, as described for a chimeric anti-CD20 antibody (Selenko et al, 2001).

Our observations suggest that graft-contaminating neuroblastoma cells induced a tumour-protective immune response after transplantation. If so, the initiation of such a response may have required a threshold quantity of tumour antigen. This would explain the association between long-term survival and the presence of more than 2000 estimated tumour cells in the graft. The reduction of the number of contaminating tumour cells by CD34+ cell selection might also play a role in survival by preventing the infusion of higher numbers of tumour cells that might overwhelm the immune system and result in relapse (Brenner et al, 1993). Unfortunately, this retrospective analysis did not allow us to investigate the expression of potential TAAs by patients’ tumour cells. Although parts of our clinical observation were based on an assumption, our findings, taken with those of other investigators, provide a rationale for future trials in which autologous grafts of patients with high-risk neuroblastoma or other tumours are spiked with defined numbers of irradiated tumour cells or are vaccinated immediately after stem cell transplantation while still lymphopenic. A thorough analysis of the expression of potential TAAs by the individual patient’s tumour cells and an analysis of the post-transplant immune response should reveal whether this approach results in an effective and lasting tumour protection.

ACKNOWLEDGEMENTS
We thank Professors HG Rammensee and RA Reisfeld for critical reading of the manuscript and helpful suggestions and Sharon Naron for editorial assistance. This work was supported by a grant from the Deutsche Krebshilfe (W44/93/N16) and the Deutsche Leukämieforschungshilfe (94.05).

REFERENCES
Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99: 931 – 936
Boon T, Old LJ (1997) Cancer tumor antigens. Cancer Immunol Immunother 44: 681 – 683
Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI (2000) Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte–macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95: 3011 – 3019
Brenner MK, Rill DR, Moen RC, Krance RA, Mirro JR, Anderson WF, Igle JN (1993) Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341: 85 – 86
Burchill SA, Kinsey SE, Picton S, Roberts P, Pinkerton CR, Selby P, Lewis IJ (2001) Minimal residual disease at the time of peripheral blood stem cell transplantation (Borrello et al, 2001). Circulation 104: 3914 – 3919
Handgretinger R, Lang P, Ihm K, Schumm M, Geiselhart A, Kosielnik E, Hero B, Klingebiel T, Niethammer D (2002) Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. Bone Marrow Transplant 29: 731 – 736
Handgretinger R, Lang P, Schumm M, Taylor G, Neu S, Kosielnik E, Niethammer D, Klingebiel T (1998) Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting. Bone Marrow Transplant 21: 987 – 993
Heitger A, Kern H, Mayerl D, Maurer K, Nachbaur D, Fruhwirth M, Fink FM, Niederwieser D (1999) Effective T cell regeneration following high-dose chemotherapy rescued with CD34+ cell enriched peripheral blood progenitor cells in children. Bone Marrow Transplant 23: 347 – 353
Hellstrom KE, Hellstrom I, Kant JA, Tamerius JD (1978) Regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. J Clin Invest 61: 185 – 192
Feng H, Zeng Y, Graner MW, Katsanis E (2002) Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 100: 4108 – 4115
Jager E, Jager D, Knuth A (2002) Clinical cancer vaccine trials. Curr Opin Immunol 14: 178 – 182
Huang H, Poochein CH, Urba WJ, Fox BA (2002) Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 62: 3914 – 3919
Hu HM, Burchill SA, Kinsey SE, Picton S, Roberts P, Pinkerton CR, Selby P, Lewis IJ (2001) Minimal residual disease at the time of peripheral blood stem cell transplantation (Borrello et al, 2001). Circulation 104: 3914 – 3919
Jager E, Jager D, Knuth A (2002) Clinical cancer vaccine trials. Curr Opin Immunol 14: 178 – 182
Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Stat Assoc 53: 457 – 481
Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jurgens H, Lang P, Niethammer D, Rath B, Handgretinger R (1998) Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 33: 1398 – 1402
Klingebiel T, Handgretinger R, Herter M, Eppinger T, Bader P, Lang P, Dopfer R, Scheel-Walter H, Haus U, Niethammer D (1995) Autologous transplantation with peripheral blood stem cells in children and young adults after myeloablative treatment: nonrandomized comparison between GM-CSF and G-CSF for mobilization. J Hematother 4: 307 – 314
Kwak LW (1998) Tumor vaccination strategies combined with autologous peripheral stem cell transplantation. Ann Oncol 9(Suppl 1): S41 – S46
Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI (1998) Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 22: 971 – 979
Liu K, Yang Y, Mansbridge J (2000) Comparison of the stress response to cryopreservation in monolayer and three-dimensional human fibroblast cultures: stress proteins, MAP kinases, and growth factor gene expression. Tissue Eng 6: 539 – 554
Lode HN, Handgretinger R, Schuermann U, Seitz G, Klingebiel T, Niethammer D, Beck J (1997) Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. Eur J Cancer 33: 2024 – 2030
Maine GN, Mule JJ (2002) Making room for T cells. J Clin Invest 110: 157 – 159
Nanda NK, Sercarz EE (1995) Induction of anti-self-immunity to cure cancer. Cell 82: 13 – 17
Pardoll DM (1999) Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 96: 5340 – 5342
Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380 – 384
Schild H, Rammensee HG (2000) gp96 – the immune system's Swiss army knife. Nat Immunol 1: 100 – 101
Selenko N, Maidic O, Draxier S, Berer A, Jager U, Knapp W, Stockl J (2001) CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 15: 1619 – 1626
Seling A, Schurr P, Berthold F (1999) Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res 19: 2205 – 2209
Sondak VK, Wagner PD, Shu S, Chang AE (1991) Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy. Arch Surg 126: 442 – 446